NDAORALTABLET
Approved
May 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
TRADJENTA (linagliptin) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2011.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRADJENTA (linagliptin) is an oral small-molecule DPP-4 inhibitor approved in 2011 for type 2 diabetes management. It works by inhibiting dipeptidyl peptidase-4, prolonging incretin hormone activity to improve glucose control. The drug is indicated as monotherapy or combination therapy for glycemic control in patients with type 2 diabetes.
$1.3BPart D
PeakStable
11.2 years to LOEStrong peak-stage revenue base at $1.3B with 11+ years of patent protection, supporting stable commercial teams focused on market maintenance and lifecycle extension.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers
Started Apr 2024
48 enrolled
Healthy Volunteer
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Started Mar 2020
85 enrolled
Diabetes Mellitus, Type 2
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Started Aug 2018
30 enrolled
Healthy
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Started Mar 2018
175 enrolled
Diabetes Mellitus, Type 2
Real World Glycemic Effectiveness of Linagliptin
Started Nov 2017
11,001 enrolled
Diabetes Mellitus, Type 2
Worked on TRADJENTA at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.